BDNF and cancer: With the use of the high-throughput method adapted from AlphaScreen technology, that has been used previously to monitor RNA-protein binding and for screening of small molecules targeting these interactions (Mills et al., 2007), Pedram Fatemi et al. (2015) have identified several small-molecule inhibitors of the interaction between EZH2 and two lncRNAs: HOTAIR and brain-derived neurotrophic factor antisense (BDNF-AS) in different cancers.